Mumbai, Somerset, New Jersey, December 02, 2021: Lupin Inc., a wholly-owned subsidiary of global pharma major, Lupin Limited (Lupin) has entered into an agreement with TTP plc (The Technology Partnership plc) to acquire the exclusive worldwide rights to develop, manufacture and commercialize inhalation products using TTP’s soft-mist inhalation technology platform. By leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable inhaled medicines to patients across the globe.

Soft-mist inhalation (SMI) technology allows for delivery of inhalation drugs from a small, portable hand-held inhaler device without the use of propellants. The individual doses are delivered using a precisely engineered nozzle system to produce a slow-moving and long-sustaining aerosol cloud. Lupin anticipates applications across respiratory care.

Lupin and TTP will jointly develop the device. Lupin will commercially manufacture the device through its network of in-house and external manufacturing locations. Lupin will also develop and manufacture formulations to be delivered through the device, obtain the necessary regulatory approvals, and commercialize the products globally.

Commenting on the development Vinita Gupta, Global CEO, Lupin said, “Inhalation is a strategic pillar of Lupin’s growth story, as we strive to bring affordable medicines to patients across the globe. The partnership with TTP for SMI technology platform is a strategic addition to our broad Inhalation capabilities.”

Alok Sonig, CEO – US Generics & Global R&D Head, Lupin added, “Lupin is excited to be partnering with TTP. The organizations will work together to develop products using TTP’s SMI technology that complement Lupin’s portfolio of complex inhalation products.”

Commenting on the development, Sam Hyde, Managing Director, TTP said, “We are excited to be partnering with Lupin to commercialize our SMI technology so that it can benefit patients suffering with chronic respiratory conditions. TTP has deep expertise in aerosol science, and we have been working with our clients for over 30 years in complex drug delivery device development – this partnership represents an exciting next step for us in this innovative area of respiratory drug delivery.”

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development. Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology& Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on
Twitter: https://twitter.com/LupinGlobal
LinkedIn: https://www.linkedin.com/company/lupin
Facebook: http://www.facebook.com/LupinWorld/

About TTP

TTP is an independent technology company where scientists, engineers, and designers collaborate to invent, design and develop new products and technologies. With a 30-year history of invention, its multidisciplinary teams are able to deliver across the scope of a project, from research through to ideas, design, engineering and manufacture.

TTP’s state-of-the-art technical facilities are part of Europe’s largest technology hub in Cambridge, UK. Here, it works across a wide spectrum of industries – including healthcare, telecoms, industrials and consumer – to create breakthrough solutions that bring strong commercial value to clients and the benefits of technology to all. TTP has a long history in drug delivery device development and deep expertise in the science, engineering and manufacture of controlled droplet generation technologies.

Please visit www.ttp.com for more information.
Follow us on LinkedIn: www.linkedin.com/company/the-technology-partnership/

For further information or queries please contact:

Shweta Munjal
Head – Corporate Communications
Email: shwetamunjal@lupin.com